News Feed Item

Acquisitions, Successful Clinical Trials, and Financial Results - Research Report on Medtronic, Osiris, Community Health Systems, Dendreon, and Insys Therapeutics

NEW YORK, August 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Osiris Therapeutics, Inc. (NASDAQ: OSIR), Community Health Systems (NYSE: CYH), Dendreon Corporation (NASDAQ: DNDN), and Insys Therapeutics Inc. (NASDAQ: INSY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Medtronic, Inc. Research Report

On August 12, 2013, Medtronic Inc. (Medtronic) announced the closing of its acquisition of Cardiocom, a privately held developer and provider of telehealth and patient services for the management of chronic diseases, in an all cash transaction valued at $200 million. Commenting on the acquisition, Omar Ishrak, Chairman and CEO of Medtronic, said, "The acquisition of Cardiocom is one step we are taking toward providing a combination of products and solutions that can help address those challenges. With our first integration of this technology focused on heart failure, we will have the unique opportunity to combine our leading diagnostics, therapies and patient management solutions. This combination will strengthen our ability to partner with providers and payers to help them reduce cost and improve quality." The Company expects that the net income from this transaction will be neutral to its FY 2014 earnings. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/MDT]

Osiris Therapeutics, Inc. Research Report

On August 13, 2013, Osiris Therapeutics Inc. (Osiris) reported that its multi-center, randomized, controlled clinical trial comparing the safety and efficacy of Grafix to standard of care in patients with chronic diabetic foot ulcers had met pre-specified stopping rules for overwhelming effectiveness as determined by the data monitoring committee during a planned interim analysis. The Company stated that for the study's primary endpoint, 62% patients receiving Grafix had complete wound closure compared to only 21% (p < 0.0001) patients who received conventional treatment for their wounds (a relative improvement of 191%). The Company further stated that the trial reached statistical significance in favor of Grafix on all top-line secondary endpoints, demonstrating faster wound closure and a reduction in the number of treatments needed to achieve wound closure. According to the Company, the study showed that patients randomized to receive standard of care were 74% more likely to experience an adverse effect than those receiving Grafix (p=0.008). The Full Research Report on Osiris Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/OSIR]

Community Health Systems Research Report

On August 12, 2013, Community Health Systems, Inc. (Community Health Systems) announced that the Company and Community Health Systems (CHS), its wholly owned subsidiary, have entered into an amendment (the Amendment) of their existing credit agreement dated July 25, 2007, as amended and restated as of November 5, 2010, February 2, 2012, as further amendment August 3, 2012 and as of November 27, 2012 (the Credit Agreement), effective on the date of the announcement. Community Health Systems said that the amendment provides for increased flexibility to incur debt by modifying certain terms of the Credit Agreement, including the maximum leverage ratio and secured leverage ratio covenant levels. Community Health Systems added that the amendment includes pricing protection for certain extended term loans, which specifies an increased margin in certain instances. According to the Company, the amendment also provides for a total leverage-based step up to the applicable margin of the extended term loans and the non-extended term loans, though the pricing of the loans under the Credit Agreement will otherwise remain unchanged. The Full Research Report on Community Health Systems - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/CYH]

Dendreon Corporation Research Report

On August 8, 2013, Dendreon Corporation (Dendreon) reported its Q2 2013 financial results. The Company's total revenue declined 8.3% YoY to $73.3 million during the quarter. Net loss was $68.8 million, or $0.45 per diluted share, in Q2 2013, compared to a net loss of $96.1 million, or $0.65 per diluted share, in Q2 2012. Commenting on the results, John H. Johnson, Chairman, President and CEO of Dendreon, said, "During the second quarter, we made progress turning around what was a challenging first quarter, with solid growth in large accounts where we are focused. Urology led the way, with 37% quarter-over-quarter growth, and our highest-ever sales in this segment. We have received supportive feedback from physicians, patients and key opinion leaders about PROVENGE, and remain focused on improving utilization through our direct-to-consumer advertising campaign, which is generating positive early indicators." The Full Research Report on Dendreon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/DNDN]

Insys Therapeutics Inc. Research Report

On August 13, 2013, Insys Therapeutics Inc. (Insys Therapeutics) reported its Q2 2013 financial results. The Company's net revenue increased 431.8% YoY to $18.8 million during the quarter. Net income was $4.5 million, or $0.26 per diluted share, in Q2 2013, compared to a net loss of $6.4 million, or $0.68 per diluted share, in Q2 2012. Commenting on the results, Michale L. Babich, President and CEO of Insys Therapeutics, said, "Our strong second quarter results were driven by continued uptake of Subsys." He added, "The continued growth we have achieved allows us to accelerate reinvestment in both our research and development and sales and marketing efforts." The Full Research Report on Insys Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/INSY]


  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: implemen...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...